Business
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an upsized underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $31.00 per share, before underwriting discounts and commissions. All of the shares to be sold in the proposed offering are to be sold by Axogen
About this update from Axogen, Inc.
[{"type":"image","alt":"Axogen, Inc.","displaySize":"","headline":null,"caption":"Axogen, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":97,"url":"https://media.zenfs.com/en/globenewswire.com/33eccfef38d77840af306d8730f29c13"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GP.xMGJTB4RFVzq3UjYgWg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/33eccfef38d77840af306d8730f29c13","width":300,"height":97}},"lazy":false},{"type":"text","content":"ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an upsized underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $31.00 per share, before underwriting discounts and commissions. All of the shares to be sold in the proposed offering are to be sold by Axogen. In addition, Axogen has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Axogen from the proposed offering, before deducting underwriters’ discounts and commissions and other offering expenses payable by Axogen, are expected to be approximately $124 million (assuming no exercise of the underwriters’ option to purchase additional shares).","length":997,"tagName":"p"},{"type":"text","content":"The proposed offering is expected to close on January 23, 2026, subject to the satisfaction of customary closing conditions.","length":124,"tagName":"p"},{"type":"text","content":"Wells Fargo Securities and Mizuho are acting as lead book-running managers for the proposed offering. Canaccord Genuity and Raymond James are acting as co-managers for the proposed offering.","length":190,"tagName":"p"},{"type":"text","content":"Axogen intends to use the net proceeds from the offering for early payoff and termination of its term loan facility with Oberland Capital, working capital, capital expenditures and other general corporate purposes.","length":214,"tagName":"p"},{"type":"text","content":"The proposed offering is being made pursuant to an automatic shelf registration statement on Form S-3ASR th...